Vector Secures Exclusive cGMP Peptide Manufacturing Deal
MEQUON, Wis., July 7, 2026 Vector Science & Therapeutics Corp. has entered into a landmark exclusive licensing and cGMP...
tirzepatide
Advertisement
Ascletis Receives FDA IND Clearance for ASC35 Obesity Trial
HONG KONG, June 23, 2026 Ascletis Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
LIR Shows Successful Needle-Free Delivery of GLP-1 Therapies
VANCOUVER, Canada, June 17, 2026 LIR Life Sciences Corp. announced the successful completion of its comparative preclinical animal study...
Caliway Presents CBL-514 Data Showing Reduced Weight Regain with GLP-1 Therapies
June 10, 2026 – Taipei, Taiwan Caliway Biopharmaceuticals announced new preclinical data demonstrating the potential of its proprietary fat-reduction...
Eli Lilly and Shaquille O’Neal Raise Awareness of Treatable Sleep Apnea with Zepbound
INDIANAPOLIS, United States, June 10, 2026 Eli Lilly and Company has launched a nationwide awareness campaign featuring NBA legend...
Advertisements
Lilly Unveils Landmark Phase 3 Data for Foundayo and Retatrutide at ADA 2026
INDIANAPOLIS, May 28, 2026 Eli Lilly and Company has announced a major slate of scientific presentations for the American...
Caliway Showcases CBL-514 Obesity Combination Data at ECO 2026
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
Advertisement
